UPC
NASDAQUniverse Pharmaceuticals Inc.
Universe Pharmaceuticals Inc. (UPC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for UPC, including 1 SEC filing. The most recent was published Oct 13, 2026.
UPC rankings
Financial highlights
Full financials- Revenue, FY2025
- $17.86B
- Revenue growth
- -22.4%
- Net income, FY2025
- -$3.67B
- Net margin
- -20.6%
- Free cash flow, FY2025
- -$5.32B
- Cash
- $33.59B
For fiscal 2025 (ended Sep 30, 2025), from SEC filings. Not investment advice.
News · 26 weeks11-100%
2026-05-172026-11-08
Mix590d
- SEC Filings4(80%)
- Other1(20%)
Activity · 52 weeks2316 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form EFFECT filed by Universe Pharmaceuticals Inc.EFFECT - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form F-3 filed by Universe Pharmaceuticals Inc.F-3 - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Universe Pharmaceuticals Inc.6-K/A - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PR4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesDENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PRUniverse Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent PortfolioJi'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited ("Best Praise"), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company. The patent portfolio covers several pharmaceutical and healthcare-related areas, including age-related disease
- INSIDERChief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)4 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yang Lin (Lydia)3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lai Gang3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PRUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureJi'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa
- SECSEC Form 20-F filed by Universe Pharmaceuticals Inc.20-F - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
UPC FAQ
10 questionsWhat does Universe Pharmaceuticals Inc. do?
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals...What is the latest news on UPC?
In the last 30 days Quantisnow tracked 1 wire item for UPC: 1 SEC filing. The most recent was published on October 13, 2026.What is UPC revenue?
Universe Pharmaceuticals Inc. (UPC) reported $17.86B of revenue for fiscal 2025 (ended Sep 30, 2025). That is down 22.4% from the year before.Is UPC profitable?
No. Universe Pharmaceuticals Inc. reported a net loss of $3.67B for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does UPC have?
Universe Pharmaceuticals Inc. reported $33.59B in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does UPC stock trade?
Universe Pharmaceuticals Inc. (UPC) is listed on NASDAQ.What sector and industry is UPC in?
Universe Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Universe Pharmaceuticals Inc. go public?
Universe Pharmaceuticals Inc. (UPC) completed its IPO in 2021.What companies are similar to UPC?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare UPC side-by-side with any of them on Quantisnow.How can I track UPC on Quantisnow?
Quantisnow aggregates Universe Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UPC to receive live email and push alerts on every new disclosure.